Article
Oncology
John A. Vargo, Vitali Moiseenko, Jimm Grimm, Jimmy Caudell, David A. Clump, Ellen Yorke, Jinyu Xue, Yevgeniy Vinogradskiy, Eduardo G. Moros, Panayiotis Mavroidis, Sheena Jain, Issam El Naqa, Lawrence B. Marks, Dwight E. Heron
Summary: This study systematically reviewed the available literature on tumor control probability with SBRT in head and neck cancer patients, finding a dose-response relationship suggesting better local control and possibly improved overall survival with doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy. It is suggested that SBRT doses equivalent to 5-fraction doses of 40 to 50 Gy are used for retreatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Oncology
Remco de Bree, Christiaan D. A. Meerkerk, Gyorgy B. Halmos, Antti A. Maekitie, Akihiro Homma, Juan P. Rodrigo, Fernando Lopez, Robert P. Takes, Jan B. Vermorken, Alfio Ferlito
Summary: In head and neck cancer patients, personalized treatment based on risk assessment is important. Sarcopenia and frailty can predict adverse outcomes and improve treatment options and patient outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Kaley Woods, Robert K. Chin, Kiri A. Cook, Ke Sheng, Amar U. Kishan, John V. Hegde, Stephen Tenn, Michael L. Steinberg, Minsong Cao
Summary: The study evaluates the potential for tumor dose escalation in recurrent head and neck cancer patients using the HyperArc technique, showing that it significantly increases tumor dose while maintaining minimal risk to nearby organs.
Review
Medicine, General & Internal
Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert Haddad, Nabil F. Saba
Summary: Head and neck cancer is the seventh most common type of cancer worldwide, with the predominant risk factors being tobacco use, alcohol abuse, and oncogenic viruses. Treatment typically involves a multidisciplinary approach with surgery, radiotherapy, and systemic therapy, and is challenging due to site-specific and histology-specific variations.
Article
Oncology
Michiel Kroesen, Netteke van Holthe, Kemal Sumser, Dana Chitu, Rene Vernhout, Gerda Verduijn, Martine Franckena, Jose Hardillo, Gerard van Rhoon, Margarethus Paulides
Summary: The study demonstrates the use of a new hyperthermia applicator to enhance the effectiveness of radiotherapy in head and neck cancer patients requiring reirradiation. Patients tolerated the added hyperthermia treatment well and received a higher hyperthermia dose than with the previous applicator, leading to similar tumor control and survival outcomes as reported with chemotherapy as an additive to reirradiation in head and neck cancer patients.
Article
Otorhinolaryngology
Arnaud Beddok, Caroline Saint-Martin, Samar Krhili, Catherine Ala Eddine, Laurence Champion, Anne Chilles, Farid Goudjil, Sofia Zefkili, Malika Amessis, Dominique Peurien, Olivier Choussy, Christophe le Tourneau, Remi Dendale, Irene Buvat, Gilles Crehange, Valentin Calugaru
Summary: This study analyzed the outcomes of curative reirradiation for recurrent head and neck squamous cell carcinoma, and found that the locoregional recurrence rate was high and there were risks of toxicity grade >= 2.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Review
Health Care Sciences & Services
Loredana G. Marcu, David C. Marcu
Summary: Chemoradiotherapy remains the most common treatment for locally advanced head and neck cancer, but the quality of life and long-term survival of patients undergoing this treatment are still poor. Personalized therapy through multi-omics approach shows promising results in improving tumor response and reducing normal tissue toxicity. Incorporating dosiomics, pharmacomics, and radiomics into head and neck cancer management offers multiple viewpoints for personalized therapy.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Johannes Roesch, Michael Oertel, Simone Wegen, Maike Trommer, Julia Schleifenbaum, Dominik Hering, Matthias Maeurer, Stefan Knippen, Sophie Dobiasch, Maria Waltenberger, Jens von der Gruen, Daniel Medenwald, Christoph Suess, Michael Hoeck, Lukas Kaesmann, Daniel F. Fleischmann, Alexander Ruehle, Nils H. Nicolay, Alexander Fabianq, Anastassia Loeser, Sebastian Hess, Balint Tamaskovics, Maria Vinsensia, Markus Hecht
Summary: This retrospective multicenter study analyzed the efficacy and prognostic parameters of definitive re-irradiation for locoregionally recurrent or second primary head and neck squamous cell carcinoma (HNSCC) treated with modern radiotherapy technique. The results showed that radiation doses above 50 Gy (EQD2) and good ECOG performance score were independent prognostic factors for overall survival.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Indu S. Voruganti, Ian Poon, Zain A. Husain, Andrew Bayley, Elizabeth A. Barnes, Liying Zhang, Lee Chin, Darby Erler, Kevin Higgins, Danny Enepekides, Antoine Eskander, Irene Karam
Summary: This study reported the outcomes of SBRT for head and neck skin cancer patients, including local control, overall survival, and late toxicity. The results showed that SBRT provides durable disease control with acceptable toxicity for high-risk patients unable to undergo standard treatment approaches.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Alexandria Harris, Jinhong Li, Karley Atchison, Christine Harrison, Daniel Hall, Tyler VanderWeele, Jonas T. Johnson, Marci L. Nilsen
Summary: This study evaluates the relationship between demographics, clinical characteristics, and posttreatment symptom burden with the subjective sense of flourishing among head and neck cancer survivors. The results suggest that late- and long-term side effects of treatment and financial hardship are associated with lower levels of flourishing.
Article
Oncology
Adam Luginbuhl, Alyssa Calder, David Kutler, Chad Zender, Trisha Wise-Draper, Jena Patel, Michael Cheng, Vidhya Karivedu, Tingting Zhan, Bhupesh Parashar, Shuchi Gulati, Min Yao, Pierre Lavertu, Vinita Takiar, Alice Tang, Jennifer Johnson, William Keane, Joseph Curry, David Cognetti, Voichita Bar-Ad
Summary: Among patients with local/regional recurrent HNSCC status-post radiation, surgery + Cs-131 demonstrated acceptable safety with compelling oncologic outcomes compared to historic control cohorts.
FRONTIERS IN ONCOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Daniela Alterio, Mattia Zaffaroni, Paolo Bossi, Francesco Dionisi, Olgun Elicin, Andrea Falzone, Annamaria Ferrari, Barbara Alicja Jereczek-Fossa, Giuseppe Sanguineti, Petr Szturz, Stefania Volpe, Melissa Scricciolo
Summary: This study reviewed the literature on modern radiation techniques and fractionations used for reirradiation of local recurrent/second primary tumors of the head and neck. Based on the literature data, a stepwise approach was proposed to select patients for curative reirradiation. Two clinical cases were provided for application of this approach.
Article
Oncology
Jennifer L. Leddon, Shuchi Gulati, Sulsal Haque, Casey Allen, Sarah Palackdharry, Maria Mathews, Nicky Kurtzweil, Muhammed Kashif Riaz, Vinita Takiar, Misako Nagasaka, Yash Patil, Chad Zender, Alice Tang, Brian Cervenka, Julie McGrath, W. Michael Korn, Benjamin H. Hinrichs, Roman Jandarov, Nusrat Harun, Ammar Sukari, Trisha M. Wise-Draper
Summary: The study investigated the safety and efficacy of adjuvant nivolumab after salvage surgical resection in locally recurrent HNSCC. The results showed improved disease-free survival compared with historical controls and good tolerability.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Glenn J. Hanna, Anne O'Neill, Kee-Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert Haddad
Summary: This study investigated the use of dual immune-checkpoint inhibition in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN) before and after surgery. The results showed a promising response rate and suggests further evaluation of this strategy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
David Forner, Florence Mok, Neil Verma, Irene Karam, David Goldstein, Kevin Higgins, Danny Enepekides, Ashlie Nadler, Robyn Pugash, Zain Husain, Kelvin Chan, Martin Smoragiewicz, Lawrence Cohen, Jeffrey W. Hazey, Eleanor C. Fung, Stephen Y. Kang, Nolan B. Seim, Colleen Simpson, Antoine Eskander
Summary: Percutaneous endoscopic gastrostomy (PEG) placement is essential for providing enteral nutrition to select head and neck cancer patients. This study found that the push technique is associated with a greater risk of developing any tube-related complication, while the pull technique may have a higher rate of stomal metastases.
Article
Oncology
Gerda M. M. Verduijn, Steven F. F. Petit, Iris Lauwers, Yvette van Norden, Nienke Sijtsema, Aniel Sewnaik, Hetty Mast, Marta Capala, Remi Nout, Sarah Baker, Esther van Meerten, Mischa S. S. Hoogeman, Aad van der Lugt, Wilma D. D. Heemsbergen
Summary: The study aimed to compare the pattern of PRMU development and identify risk factors for OPSCC patients after radiation therapy. The results showed a higher incidence of PRMU in the SBRT boost group, associated with sex, acute tube feeding, tumor subsite, and N stage.
Article
Oncology
M. -c. Jahreiss, W. D. Heemsbergen, C. Janus, M. van de Pol, M. Dirkx, A. G. Dinmohamed, R. A. Nout, M. Hoogeman, L. Incrocci, K. K. H. Aben
Summary: This study examined the risk of second haematological cancer (SHC) after external beam radiotherapy (EBRT) for prostate cancer (PCa) in the Netherlands. The findings showed an increased risk of SHC in PCa patients who underwent EBRT, especially in the era of two-dimensional radiotherapy (2D-RT). The risk was significantly higher compared to active surveillance, but not compared to radical prostatectomy. These findings highlight the importance of further evaluating and improving EBRT techniques.
Article
Cardiac & Cardiovascular Systems
Martijn H. van der Ree, Edith M. T. Dieleman, Jorrit Visser, R. Nils Planken, S. Matthijs Boekholdt, Rianne H. A. de Bruin-Bon, Coen R. N. Rasch, Wiert F. Hoeksema, Rianne M. A. J. de Jong, Michiel J. B. Kemme, Jippe C. Balt, Arthur A. M. Wilde, Brian Balgobind, Pieter G. Postema
Summary: This study aims to evaluate the efficacy and safety of Stereotactic Arrhythmia Radiotherapy (STAR). It found that STAR can reduce the number of treated ventricular tachycardia episodes by more than 50% in 67% of patients with therapy-refractory VT. No decrease in cardiac and pulmonary function or treatment-related serious adverse events were observed during follow-up.
Article
Oncology
Marie-Christina Jahreiss, Mischa Hoogeman, Katja K. H. Aben, Maarten Dirkx, Renier Snieders, Floris J. Pos, Tomas Janssen, Andre Dekker, Ben Vanneste, Andre Minken, Carel Hoekstra, Robert J. Smeenk, Luca Incrocci, Wilma Heemsbergen
Summary: This study investigated the association between characteristics of external beam radiotherapy (EBRT) protocols for localized prostate cancer (PCa) and second primary cancer (SPC) risks. The results showed that advanced EBRT characteristics were not associated with increased out-of-field SPC risks.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Buket Kinaci-Tas, Tanja Alderliesten, Frank D. Verbraak, Coen R. N. Rasch
Summary: Retinopathy and optic neuropathy are common and severe ocular complications in patients undergoing radiation therapy for brain, head, and neck cancer. However, there is limited knowledge about the prevalence and dose-response relationship of these complications. Further research is needed to improve the precision of radiation therapy.
Article
Oncology
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retel, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Summary: The ADAPT ALEC trial aims to improve treatment outcomes for patients with advanced ALK+ NSCLC by using TDM-guided dosing of alectinib instead of fixed dosing.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
F. Sinzabakira, V. Brand, W. D. Heemsbergen, L. Incrocci
Summary: Moderate hypofractionated (HF) radiotherapy is a new standard in radiotherapy for prostate cancer patients. Our systematic review demonstrates that HF is associated with increased acute gastrointestinal (GI) toxicity levels, requiring adequate monitoring and management. Limited data on toxicity management and no significant increase in late toxicity were observed.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
M. -C Jahreiss, L. Incrocci, M. Dirkx, K. C. de Vries, K. K. H. Aben, C. Bangma, W. D. Heemsbergen
Summary: We studied the overall survival and related prognostic factors in Dutch patients with localized prostate cancer selected for external beam radiotherapy. The results showed that age, comorbidity score, smoking habits, and Gleason score >= 8 had a significant negative impact on overall survival. Long-term androgen deprivation therapy improved overall survival in high-risk patients, while Gleason score >= 8 was associated with worse overall survival.
Article
Oncology
Soumyajit Roy, Tahmineh Romero, Jeff M. Michalski, Felix Y. Feng, Jason A. Efstathiou, Colleen A. F. Lawton, Michel Bolla, Philippe Maingon, Theo de Reijke, David Joseph, Wee Loon Ong, Matthew R. Sydes, David P. Dearnaley, Alison C. Tree, Nathalie Carrier, Abdenour Nabid, Luis Souhami, Luca Incrocci, Wilma D. Heemsbergen, Floris J. Pos, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Robert E. Reiter, Matthew B. Rettig, Nicholas G. Nickols, Michael L. Steinberg, Luca F. Valle, T. Martin Ma, Matthew J. Farrell, Beth K. Neilsen, Jesus E. Juarez, Jie Deng, Sitaram Vangala, Norbert Avril, Angela Y. Jia, Nicholas G. Zaorsky, Yilun Sun, Daniel Spratt, Amar U. Kishan
Summary: This study evaluated the surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer. The results showed that BCR-free survival (BCRFS) and time to BCR (TTBCR) can serve as prognostic indicators, but they do not fully satisfy the surrogacy criteria. The strength of the correlation was greater when noncancer-related deaths were considered as events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Gerda M. Verduijn, Nienke D. Sijtsema, Yvette van Norden, Wilma D. Heemsbergen, Hetty Mast, Aniel Sewnaik, Denzel Chin, Sarah Baker, Marta E. Capala, Aad van der Lugt, Esther van Meerten, Mischa S. Hoogeman, Steven F. Petit
Summary: This study aimed to develop a model for predicting the risk of osteoradionecrosis (ORN) after radiotherapy using Equivalent Uniform Doses (EUD) across different fractionation schemes.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Pediatrics
Alba Rubio-San-Simon, Natasha K. A. van Eijkelenburg, Raoull Hoogendijk, Henrik Hasle, Charlotte M. Niemeyer, Michael N. Dworzak, Marco Zecca, Marta Lopez-Yurda, Julie M. Janssen, Alwin D. R. Huitema, Marry M. van den Heuvel-eibrink, Eric J. Laille, Harm van Tinteren, Christian M. Zwaan
Summary: This study aimed to evaluate the safety, pharmacokinetics, and efficacy of azacitidine in children with relapsed MDS/JMML prior to a second hematopoietic stem cell transplantation. The results showed no response in patients with MDS, but 83% achieved stable disease, and the overall response rate in the JMML cohort was 75%. The study suggests that azacitidine is a safe and efficacious option for relapsed JMML.
Article
Oncology
Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Esmee P. Hoefsmit, Petros Dimitriadis, Disha Rao, Ruben Lacroix, Lindsay G. Grijpink-Ongering, Marta Lopez-Yurda, Birthe C. Heeres, Bart A. van de Wiel, Claudie Flohil, Aysegul Sari, Stijn W. T. P. J. Heijmink, Daan van den Broek, Annegien Broeks, Jan Willem B. de Groot, Marieke A. Vollebergh, Sofie Wilgenhof, Johannes van Thienen, John B. A. G. Haanen, Christian U. Blank
Summary: The aim of this study was to identify the optimal regimen of short-term MAPKi with pembrolizumab in patients with BRAF(V600)-mutated melanoma. The combination of pembrolizumab plus intermittent dabrafenib and trametinib was found to be more feasible and tolerable than continuous triple therapy, with promising efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Jonathan E. Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J. Deenen, Jan H. M. Schellens, Jos Beijnen, Annemieke Cats, Henk-Jan Guchelaar
Summary: DPYD-guided dosing has improved the safety of fluoropyrimidine-based chemotherapy. However, severe toxicity still occurs in patients without DPYD variant alleles. Therefore, researchers developed a predictive model based on patient and treatment factors to estimate the risk of severe toxicity. Internal validation showed good predictive ability of the model.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
S. Lot Aronson, Marta Lopez-Yurda, Simone N. Koole, Jules H. Schagen van Leeuwen, Hendrik W. R. Schreuder, Ralph H. M. Hermans, Ignace H. J. T. de Hingh, Mignon D. J. M. van Gent, Henriette J. G. Arts, Maaike A. P. C. van Ham, Peter A. van Dam, Peter Vuylsteke, Arend G. J. Aalbers, Victor J. Verwaal, Koen K. Van de Vijver, Neil K. Aaronson, Gabe S. Sonke, Willemien van Driel
Summary: This study confirms the long-term survival benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery.
Article
Radiology, Nuclear Medicine & Medical Imaging
Brigit M. Aarts, Fernando M. Gomez, Marta Lopez-Yurda, Rob F. M. Bevers, Joris Herndriks, Regina G. H. Beets-Tan, Axel Bex, Elisabeth G. Klompenhouwer, Rutger W. van der Meer
Summary: This study compared the safety and efficacy of radiofrequency ablation (RFA) and microwave ablation (MWA) for the treatment of renal cell carcinoma (RCC). The results showed similar primary efficacy rates and safety between RFA and MWA.
EUROPEAN RADIOLOGY
(2023)